Donley Matthew Maxwell's Form 4 filing
Aurinia Pharmaceuticals Inc. (AUPH) · filed Mar 4, 2025
- Accession no.
- 0001600620-25-000018
- Filed
- Mar 4, 2025
- Trade date
- Feb 28-Mar 4, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $994.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Donley Matthew MaxwellCIK 0001636642 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +82,781 | $0.00 | $0 | 669,791 | Direct | |
| Mar 3, 2025 | Common Stock | AGrant or awardAcquired | +135,567 | $0.00 | $0 | 805,358 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −65,902 | $8.00 | −$527,216 | 739,456 | Direct | |
| Mar 4, 2025 | Common Stock | SSaleDisposed | −58,991 | $7.92 | −$467,208.72 | 680,465 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +126,416 | $0.00 | $0 | 126,416 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.